Drug intelligence / Profile preview

psilocybe cubensis

Development stage
Phase 2
Lead developer
Numinus
Modality
Small Molecules
Administration
Oral
01

Overview

*Psilocybe cubensis* is a species of psychedelic mushroom whose principal active compounds are the alkaloids psilocybin and psilocin. Upon ingestion, psilocybin is rapidly dephosphorylated into psilocin, which acts as a high-affinity partial agonist at the serotonin 5-HT2A receptor. This interaction modulates glutamatergic neurotransmission in the prefrontal cortex, leading to profound alterations in consciousness and perception. In a clinical context, *Psilocybe cubensis* and its standardized extracts are being investigated for their potential to induce rapid and sustained antidepressant and anxiolytic effects, particularly in treatment-resistant populations. Research suggests that the "mystical-type experience" facilitated by these compounds may be a key mediator of therapeutic outcomes, potentially promoting neuroplasticity and the reorganization of dysfunctional neural circuits associated with mood and substance use disorders.

Other names
magic mushroomsgolden topscubesStropharia cubensisPsilocybe mushroom
02

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR2C (5-hydroxytryptamine 2C receptor)

Beyond the preview

Go deeper on psilocybe cubensis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on psilocybe cubensis.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call